10th January, 1983

Dear [Name],

Enclosed is a copy of a letter we plan to submit to the Lancet which gives the current situation with regard to the risk of non-A, non-B hepatitis after first exposure to factor VIII. The reason for this is that drug companies are planning to introduce 'hepatitis reduced' products, and it seems likely that attempts may be made to use the method of doing trial transfusions on a named patient basis and not submitting them to formal clinical trial.

The problem related to the investigation of factor VIII related Acquired Immune Deficiency Syndrome (AIDS) has been satisfactorily resolved. We will report any patient detected in the U.K. who has received U.K. commercial factor VIII direct to C.D.C. and will at the same time notify C.D.S.C. at Colindale. I have obtained consent to this arrangement, and I intend to produce a short note in the communicable disease report describing the present situation.

Kind regards,

Yours sincerely,

[Signature]

ENC: